Beyond Air Inc Cash Flow Conversion Efficiency
Beyond Air Inc cash flow conversion efficiency. Based on the latest financial reports, Beyond Air Inc (XAIR) has a cash flow conversion efficiency ratio of -0.796x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.95 Million) by net assets ($6.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Beyond Air Inc (2014–2026)
Cash flow conversion efficiency of Beyond Air Inc from 2014 to 2026. This chart illustrates how Beyond Air Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View XAIR share price today for real-time trading data and today's change.
Beyond Air Inc Cash Flow Conversion Ratio Explained
Beyond Air Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Beyond Air Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beyond Air Inc ranked by their cash flow conversion efficiency. Also see XAIR stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NO GRAVITY GAMES ZY -10
F:8YX
|
1.244x |
|
OFAL
NASDAQ:OFAL
|
-0.413x |
|
Accsys Technologies PLC
LSE:AXS
|
0.058x |
|
Arbuthnot Banking Group Plc
LSE:ARBB
|
0.304x |
|
Reinhold Europe AB
WAR:RHD
|
0.023x |
|
ModuLink Inc.
NASDAQ:MDLK
|
-1.967x |
|
URU METALS LTD
F:NVRA
|
N/A |
|
Tivic Health Systems Inc
NASDAQ:TIVC
|
-0.453x |
Annual Cash Flow Conversion Efficiency for Beyond Air Inc (2014–2026)
The table below shows the annual cash flow conversion efficiency of Beyond Air Inc from 2014 to 2026. Review cash generation quality of Beyond Air Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $6.21 Million | $-18.14 Million | -2.922x | -9.64% |
| 2025-03-31 | $14.34 Million | $-38.22 Million | -2.665x | -29.34% |
| 2024-03-31 | $27.19 Million | $-56.02 Million | -2.060x | -162.34% |
| 2023-03-31 | $42.03 Million | $-33.01 Million | -0.785x | -165.52% |
| 2022-03-31 | $78.21 Million | $-23.13 Million | -0.296x | +54.12% |
| 2021-03-31 | $30.46 Million | $-19.64 Million | -0.645x | +23.23% |
| 2020-03-31 | $18.09 Million | $-15.19 Million | -0.840x | -352.02% |
| 2019-03-31 | $4.02 Million | $1.34 Million | 0.333x | +107.23% |
| 2018-03-31 | $1.54 Million | $-7.12 Million | -4.610x | -116.76% |
| 2017-03-31 | $-25.16K | $-692.00K | 27.504x | -58.26% |
| 2016-03-31 | $-25.16K | $-1.66 Million | 65.898x | +3679.61% |
| 2015-03-31 | $-1.08 Million | $-1.88 Million | 1.744x | -49.69% |
| 2014-03-31 | $-232.00K | $-804.00K | 3.466x | -- |
About Beyond Air Inc
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and b… Read more